BrianPHigginsMD

PubMed

• 71 citations
  Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario
  Mark Levine, Jim A. Julian, Philippe L. Bedard, Andrea Eisen, Maureen E. Trudeau, Brian Higgins, Louise Bordeleau, Kathleen I. Pritchard> ;Journal of Clinical Oncology. 2016 Sep 19
• 51 citations
  BRAFV600E Negatively Regulates the AKT Pathway in Melanoma Cell Lines
  Brenden Chen, Christine Tardell, Brian P. Higgins, Packman Kathryn E, Boylan John Frederick, Huifeng Niu> ;Plos One. 2012 Aug 3
• 13 citations
  Characterization and taxonomic validity of the ciliate Oxytricha trifallax (Class Spirotrichea) based on multiple gene sequences: limitations in identifying genera sol...
  Stephen D. Zoller, Robert L. Hammersmith, Estienne C. Swart, Brian P. Higgins, Thomas G. Doak, Glenn Herrick, Laura F. Landweber> ;Protist. 2012 Jul 1
• Efficacy of vemurafenib (V), a selective V600EBRAF inhibitor, as monotherapy or in combination with erlotinib (Erl) or erbitux (Erb) and irinotecan (Iri) doublets and ...
  Higgins B, Kolinsky KD, Schostack K, Bollag G, Lee RJ, Su F, Packman K> ;J. Clin. Oncol.. 2012-02-01
• Efficacy of vemurafenib, a selective BRAFV600E inhibitor, in combination with a MEK inhibitor in BRAFV600E colorectal cancer models.
  Higgins B, Kolinsky KD, Yang H, Kim MJ, Li JK, Go Z, Packman K, Bollag G, Su F> ;J. Clin. Oncol.. 2012-02-01
• 43 citations
  The Oxytricha trifallax Mitochondrial Genome
  Estienne C. Swart, Mariusz Nowacki, Justine Shum, Heather Stiles, Brian P. Higgins, Thomas G. Doak, Klaas Schotanus, Vincent Magrini, Patrick Minx, Elaine R. Mardis, L...> ;Genome Biology and Evolution. 2012 Jan 1
• Efficacy of vemurafenib (V), a selective V600Eb-raf inhibitor, as monotherapy or in combination with erlotinib (Erl) or erbitux (Erb) and irinotecan (Iri) doublets and...
  Higgins B, Kolinsky KD, Schostack K, Bollag G, Lee RJ, Heimbrook DC, Su F, Packman K> ;J. Clin. Oncol.. 2011-05-20
• Molecular mechanisms underlying disease relapse on treatment with selective BRAF inhibitor vemurafenib (PLX4032).
  Su F, Yang H, Higgins B, Kolinsky KD, Packman K, Kim M, Lestini BJ, Bollag G, Heimbrook DC> ;J. Clin. Oncol.. 2011-05-20
• 9 citations
  Site-specific insertion of IS492 in Pseudoalteromonas atlantica.
  Brian P. Higgins, Adam C. Popkowski, Peter R. Caruana, Anna C. Karls> ;Journal of Bacteriology. 2009 Oct 15
• 26 citations
  High Rate of Febrile Neutropenia in Patients With Operable Breast Cancer Receiving Docetaxel and Cyclophosphamide
  Derrick Soong, Reem Haj, Mova G. Leung, Robert Myers, Brian Patrick Higgins, Jeff Myers, Sudha Rajagopal> ;Journal of Clinical Oncology. 2009 Sep 10
• In vivo activity of R1530 (R) alone and in combination with bevacizumab (B) and peginterferon alfa-2a (P) in a renal cell carcinoma (RCC) xenograft model.
  Higgins B, Packman K, Zhang Y, Char H, Simcox M, Kolinsky K> ;J. Clin. Oncol.. 2009-05-20
• In vivo activity of R1530 (R) alone and in combination with docetaxel (D) and bevacizumab (B) in a prostate carcinoma (PCa) xenograft model.
  Kolinsky KD, Zhang Y, Packman K, Higgins B> ;J. Clin. Oncol.. 2009-05-20
• 91 citations
  A functional role for transposases in a large eukaryotic genome.
  Mariusz Nowacki, Brian P. Higgins, Genevieve Maquilan, Estienne C. Swart, Thomas G. Doak, Laura F. Landweber> ;Science. 2009 May 15
• 27 citations
  The pathway to detangle a scrambled gene.
  Matthias Möllenbeck, Yi Zhou, Andre R. O. Cavalcanti, Franziska Jönsson, Brian P. Higgins, Wei-Jen Chang, Stefan Juranek, Thomas G. Doak, Grzegorz Rozenberg, Hans J. L...> ;Plos One. 2008 Jun 4
• Use of an alternative preclinical regimen of capecitabine (C) to enhance single agent and combination activity in a colorectal cancer xenograft model.
  Kolinsky KD, Chen J, Zhang Y, Andria M, Dugan U, Heimbrook D, Packman K, Higgins B> ;J. Clin. Oncol.. 2008-05-20
• 14 citations
  Chromosomal context directs high-frequency precise excision of IS492 in Pseudoalteromonas atlantica
  Brian P. Higgins, Chandra D. Carpenter, Anna C. Karls> ;Proceedings of the National Academy of Sciences of the United States of America. 2007 Feb 6
• 544 citations
  Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.
  Christian Tovar, Jim Rosinski, Zoran Filipovic, Brian Higgins, Kenneth Kolinsky, Holly Hilton, Xiaolan Zhao, Binh Thanh Vu, Weiguo Qing, Packman Kathryn E, Ola Myklebo...> ;Proceedings of the National Academy of Sciences of the United States of America. 2006 Feb 7
• Response to tositumamab and 131 I-tositumomab in follicular lymphoma based on the Follicular Lymphoma International Prognostic Index (FLIPI).
  Pal SE, Winer ES, Higgins B, Dungy A, Foss F> ;J. Clin. Oncol.. 2005-06-01
• 115 citations
  Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models.
  Brian Higgins, Kenneth Kolinsky, Melissa Smith, Gordon Beck, Mohammad Rashed, Violeta Adames, Michael Linn, Eric B. Wheeldon, Laurent Gand, Herbert Birnboeck, Gerhard ...> ;Anti-Cancer Drugs. 2004 Jun 1
• 7 citations
  A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients wit...
  Natasha B. Leighl, Ronald L. Burkes, J. Dancey, Pedro G. Lopez, Brian Patrick Higgins, P.L. David Walde, Leona Rudinskas, Yasmin H. Rahim, A. Rodgers, Gregory R. Pond,...> ;Clinical Lung Cancer. 2003 Sep 1
• 125 citations
  Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group.
  Maureen E. Trudeau, Elizabeth Eisenhauer, Brian Patrick Higgins, Francois Letendre, Wycliffe S. Lofters, B. Norris, Theodore A. Vandenberg, Fernand Delorme, Alison Muldal> ;Journal of Clinical Oncology. 1996 Feb 1
• Join now to see all